articleTop 1% cited

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients

AIDS · 1998 · Vol. 12(15) · pp. F167–F173

Ravi Walli✉Oliver HerfortGerlinde M. MichlThomas DemantHans Jäger(Ludwig-Maximilians-Universität München)C. DieterleJohannes R. BognerR LandgrafFrank D. Goebel

View via DOI Publisher page

Abstract

Treatment with protease inhibitors is associated with peripheral insulin resistance, leading to impaired or diabetic oral glucose tolerance in some of the patients, and with hyperlipidaemia. Overall, there is a large variation in the severity and clinical presentation of protease inhibitor-associated metabolic side-effects.

HIV-related health complications and treatments HIV/AIDS drug development and treatment HIV Research and TreatmentInsulin resistanceImpaired glucose toleranceMedicineProteaseHuman immunodeficiency virus (HIV)PeripheralDiabetes mellitusVirologyProtease inhibitor (pharmacology)Immunology

MeSH terms

AdultCholesterolFemaleGlucose Tolerance TestHumansInsulin ResistanceMaleMiddle AgedTriglyceridesHIV-1HIV InfectionsHIV Protease InhibitorsAnti-HIV Agents

Citations

537

FWCI

62.08

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study